Trastuzumab (T) and CNS metastases in women with HER-2 positive metastatic breast cancer (MBC).

被引：0
|
作者：
Dawson, SJJ
Ranieri, NF
Snyder, RD
McLachlan, SAA
Burns, WI
Newnham, GM
Francis, PA
Dowling, AJ
机构：
[1] St Vincents Hosp, Fitzroy, Vic 3065, Australia
[2] St Vincents Hosp, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：49S / 49S
页数：1
相关论文
共 50 条
  • [1] Study of lapatinib (T) in combination with trastuzumab (T) in women heavily pretreated with HER2-positive metastatic breast cancer (MBC).
    Salvador, Javier
    Ruiz Borrego, Manuel
    Valero, Maria
    Bayo, Juan L.
    De La Cruz-Merino, Luis
    Carabantes, FRancisco
    Rodriguez de la Borbolla, Maria
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Lapatinib with trastuzumab for heavily treated HER2-positive metastatic breast cancer (mBC).
    Sotelo, Miguel J.
    Manso, Luis
    Garcia Saenz, Jose Angel
    Ciruelos, Eva M.
    Moreno, Fernando
    Mendiola, Cesar
    Callata, Hector
    Ghanem, Ismael
    Cabezas, Santiago
    Gonzalez-Larriba, Jose-Luis
    Diaz Rubio, Eduardo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Incidence of brain metastasis (BM) in HER-2 overexpressing metastatic breast cancer (MBC) responsive to trastuzumab
    Stemmler, J
    Kahlert, S
    Siekiera, W
    Heinrich, B
    Untch, M
    Heinemann, V
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S130 - S130
  • [4] Cost-effectiveness of HER-2 testing strategies to select women with metastatic breast cancer (MBC) for treatment with trastuzumab.
    Oster, G
    Delea, TE
    Berger, A
    Klein, P
    Lieberman, G
    Paton, VE
    Chawla, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 68S - 68S
  • [5] Trastuzumab use beyond progression on previous trastuzumab treatment in HER-2 positive metastatic breast cancer
    Hutka, Margaret M.
    Kolosza, Zofia
    Utracka-Hutka, Beata
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 163 - 163
  • [6] Lapatinib plus trastuzumab for HER-2 positive metastatic breast cancer: experience of use
    Garcia Munoz, C.
    Cortijo Cascajares, S.
    Canamares Orbis, I.
    Goyache Goni, M. D. P.
    Ferrari Piquero, J. M.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 892 - 893
  • [7] TRASTUZUMAB BEYOND PROGRESSION IN PATIENTS WITH HER-2/NEU POSITIVE METASTATIC BREAST CANCER
    Eralp, Yesim
    [J]. JOURNAL OF BREAST HEALTH, 2009, 5 (01): : 3 - 8
  • [8] Impact of CNS metastases on treatment and survival in patients receiving trastuzumab for metastatic breast cancer (MBC)
    Griffiths, R.
    Lindquist, K.
    Lalla, D.
    Doan, J. F.
    Brammer, M. G.
    Danese, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Sanctuary site leptomeningeal metastases in HER-2 positive breast cancer: A review in the era of trastuzumab
    Kordbacheh, T.
    Law, W. Y.
    Smith, I. E.
    [J]. BREAST, 2016, 26 : 54 - 58
  • [10] Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)
    Giuliani, Rosa
    Durbecq, Virginie
    Di Leo, Angelo
    Paesmans, Marianne
    Larsimont, Denis
    Leroy, Jean-Yves
    Borms, Marleen
    Vindeuoghel, Anita
    Jerusalem, Guy
    D'Hondt, Veronique
    Dirix, Luc
    Canon, Jean-Luc
    Richard, Vincent
    Cocquyt, Veronique
    Majois, Francoise
    Reginster, Michel
    Demol, Jan
    Kains, Jean-Pierre
    Delree, Paul
    Keppens, Carine
    Sotiriou, Christos
    Piccart, Martine J.
    Cardoso, Fatima
    [J]. EUROPEAN JOURNAL OF CANCER, 2007, 43 (04) : 725 - 735
12345